ATE514090T1 - Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen - Google Patents

Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen

Info

Publication number
ATE514090T1
ATE514090T1 AT10158956T AT10158956T ATE514090T1 AT E514090 T1 ATE514090 T1 AT E514090T1 AT 10158956 T AT10158956 T AT 10158956T AT 10158956 T AT10158956 T AT 10158956T AT E514090 T1 ATE514090 T1 AT E514090T1
Authority
AT
Austria
Prior art keywords
marker
colorectal carcinoma
cancer diseases
differentiate
satb2
Prior art date
Application number
AT10158956T
Other languages
German (de)
English (en)
Inventor
Mathias Uhlen
Fredrik Ponten
Original Assignee
Atlas Antibodies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlas Antibodies Ab filed Critical Atlas Antibodies Ab
Application granted granted Critical
Publication of ATE514090T1 publication Critical patent/ATE514090T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT10158956T 2006-06-02 2007-06-04 Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen ATE514090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06114954A EP1862803A1 (en) 2006-06-02 2006-06-02 Use of protein SATB2 as a marker for colorectal cancer
US81661306P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
ATE514090T1 true ATE514090T1 (de) 2011-07-15

Family

ID=36968849

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10158956T ATE514090T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
AT07725799T ATE513216T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07725799T ATE513216T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome

Country Status (11)

Country Link
US (3) US8067190B2 (enExample)
EP (3) EP1862803A1 (enExample)
JP (2) JP4990970B2 (enExample)
CN (2) CN103293307B (enExample)
AT (2) ATE514090T1 (enExample)
AU (1) AU2007256391B2 (enExample)
CA (1) CA2653952A1 (enExample)
DK (2) DK2024747T3 (enExample)
ES (1) ES2367412T3 (enExample)
PL (1) PL2211180T3 (enExample)
WO (1) WO2007140966A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100662821B1 (ko) * 2006-04-05 2006-12-28 유니트마 주식회사 레시피언트 블록 성형용 몰드 및 이를 이용한 레시피언트블록의 제조방법
EP1862803A1 (en) 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2107375A1 (en) * 2008-03-31 2009-10-07 Atlas Antibodies AB Uses of WARS protein in cancer prognostics
EP2172477A1 (en) * 2008-10-06 2010-04-07 Atlas Antibodies AB Epitopes derived from SATB2 and uses thereof
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
CA2948548C (en) * 2014-05-13 2022-06-28 Vastcon Methionine aminopeptidase overexpression in the peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer screening, diagnosis and prognosis
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
US20160258438A1 (en) * 2015-03-05 2016-09-08 Regal Beloit America, Inc. Assembly, blower and associated method
WO2016176446A2 (en) * 2015-04-29 2016-11-03 Geneoscopy, Llc Colorectal cancer screening method and device
WO2018081580A1 (en) 2016-10-27 2018-05-03 Geneoscopy, Llc Detection method
CN106841131A (zh) * 2016-12-29 2017-06-13 上海交通大学 一种基于角蛋白自荧光作为预测检测肿瘤的生物标志物的检测方法及其应用
CA3136405A1 (en) 2018-06-01 2019-12-05 Geneoscopy, Inc. Detection method for cancer using rna biomarkers
US20210262041A1 (en) * 2018-08-08 2021-08-26 Indian Institute Of Science Education And Research Combined expression pattern of satb family chromatin organizers as improved biomarker tool for cancer prognosis
US12435335B2 (en) 2022-06-06 2025-10-07 Cornell University Promoting nutrient absorption through the colon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828840D0 (en) 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
WO2003022126A2 (en) * 2001-08-21 2003-03-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20090215711A1 (en) * 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
DE102004037860A1 (de) 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
US7932032B2 (en) * 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
GB2435882A (en) 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
EP1862803A1 (en) 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer

Also Published As

Publication number Publication date
US20120270956A1 (en) 2012-10-25
US20090220975A1 (en) 2009-09-03
US8465934B2 (en) 2013-06-18
CN103293307A (zh) 2013-09-11
ATE513216T1 (de) 2011-07-15
JP2012073260A (ja) 2012-04-12
CN101460850A (zh) 2009-06-17
US20120028836A1 (en) 2012-02-02
EP2024747A1 (en) 2009-02-18
DK2024747T3 (da) 2011-09-19
WO2007140966A1 (en) 2007-12-13
DK2211180T3 (da) 2011-09-26
JP4990970B2 (ja) 2012-08-01
EP1862803A1 (en) 2007-12-05
EP2211180B1 (en) 2011-06-22
US8067190B2 (en) 2011-11-29
PL2211180T3 (pl) 2011-11-30
JP2009539082A (ja) 2009-11-12
EP2024747B1 (en) 2011-06-15
AU2007256391A1 (en) 2007-12-13
AU2007256391B2 (en) 2011-05-19
ES2367412T3 (es) 2011-11-03
EP2211180A1 (en) 2010-07-28
CA2653952A1 (en) 2007-12-13
CN103293307B (zh) 2016-03-23
US8241859B2 (en) 2012-08-14
JP5301630B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
ATE514090T1 (de) Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
ATE450547T1 (de) Eml4-alk-fusionsgen
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
WO2006110581A3 (en) Cancer-related genes
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
WO2006091734A3 (en) Compositions and methods for classifying biological samples
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
GB0607943D0 (en) Biomarkers for chronic transplant dysfunction
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
WO2011008746A3 (en) Serum markers associated with early and other stages of breast cancer
ATE491809T1 (de) Amplifikation von dna-fragmenten
WO2007112054A3 (en) Facilitation of translocation of molecules through the gastrointestinal tract
DE602007008872D1 (de) Mikrowellengestützte deglycosylierung von proteinen zur molekulargewichtsbestimmung durch massenspektrometrie
BR0314155A (pt) Métodos para diagnosticar câncer cervical
EP2386633A4 (en) NEW CANCER ANTIGEN EEF2
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
WO2007087263A3 (en) Human zip1, zinc and citrate for prostate cancer screening
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
DE602006013333D1 (de) Kit und verfahren zum nachweis von urothelkarzinom

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties